The primary objective of the study is to determine whether co-stimulatory blockade with abatacept (CTLA4Ig) will induce tolerance and prevent relapses after medication has been discontinued in psoriasis vulgaris when administered following a decrease in the inflammatory response induced with ustekinumab (anti-IL-12/23).
|Effective start/end date||9/1/14 → 10/31/18|
- Benaroya Research Institute at Virginia Mason (FY18ITN093 // 5UM1AI109565-05)
- National Institute of Allergy and Infectious Diseases (FY18ITN093 // 5UM1AI109565-05)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.